PMID- 35746582
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 10
IP  - 6
DP  - 2022 Jun 19
TI  - Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of 
      Interleukins 4 and 13.
LID - 10.3390/vaccines10060974 [doi]
LID - 974
AB  - Interleukin-4 (IL-4) and interleukin-13 (IL-13) are key cytokines involved in the 
      pathophysiology of both immune-inflammatory and structural changes underlying 
      type 2 asthma. IL-4 plays a pivotal role in Th2 cell polarization, immunoglobulin 
      E (IgE) synthesis and eosinophil recruitment into the airways. IL-13 synergizes 
      with IL-4 in inducing IgE production and also promotes nitric oxide (NO) 
      synthesis, eosinophil chemotaxis, bronchial hyperresponsiveness and mucus 
      secretion, as well as the proliferation of airway resident cells such as 
      fibroblasts and smooth muscle cells. The biological effects of IL-4 and IL-13 are 
      mediated by complex signaling mechanisms activated by receptor dimerization 
      triggered by cytokine binding to the alpha-subunit of the IL-4 receptor (IL-4Ralpha). The 
      fully human IgG4 monoclonal antibody dupilumab binds to IL-4Ralpha, thereby 
      preventing its interactions with both IL-4 and IL-13. This mechanism of action 
      makes it possible for dupilumab to effectively inhibit type 2 inflammation, thus 
      significantly reducing the exacerbation of severe asthma, the consumption of oral 
      corticosteroids (OCS) and the levels of fractional exhaled NO (FeNO). Dupilumab 
      has been approved not only for the add-on therapy of severe asthma, but also for 
      the biological treatment of atopic dermatitis and nasal polyposis.
FAU - Pelaia, Corrado
AU  - Pelaia C
AUID- ORCID: 0000-0002-4236-7367
AD  - Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 
      Catanzaro, Italy.
FAU - Pelaia, Giulia
AU  - Pelaia G
AD  - Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 
      Catanzaro, Italy.
FAU - Crimi, Claudia
AU  - Crimi C
AUID- ORCID: 0000-0002-9088-5214
AD  - Department of Clinical and Experimental Medicine, University of Catania, 95123 
      Catania, Italy.
FAU - Maglio, Angelantonio
AU  - Maglio A
AUID- ORCID: 0000-0003-1874-1686
AD  - Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 
      Salerno, Italy.
FAU - Armentaro, Giuseppe
AU  - Armentaro G
AUID- ORCID: 0000-0001-9775-9715
AD  - Department of Medical and Surgical Sciences, University "Magna Graecia" of 
      Catanzaro, 88100 Catanzaro, Italy.
FAU - Calabrese, Cecilia
AU  - Calabrese C
AUID- ORCID: 0000-0003-4293-4461
AD  - Department of Translational Medical Sciences, University of Campania "Luigi 
      Vanvitelli", 80131 Naples, Italy.
FAU - Sciacqua, Angela
AU  - Sciacqua A
AD  - Department of Medical and Surgical Sciences, University "Magna Graecia" of 
      Catanzaro, 88100 Catanzaro, Italy.
FAU - Gallelli, Luca
AU  - Gallelli L
AUID- ORCID: 0000-0003-0858-7902
AD  - Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 
      Catanzaro, Italy.
FAU - Vatrella, Alessandro
AU  - Vatrella A
AUID- ORCID: 0000-0001-8265-3037
AD  - Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 
      Salerno, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220619
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC9229960
OTO - NOTNLM
OT  - IL-13
OT  - IL-4
OT  - dupilumab
OT  - severe asthma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/25 06:01
PMCR- 2022/06/19
CRDT- 2022/06/24 01:42
PHST- 2022/05/19 00:00 [received]
PHST- 2022/06/14 00:00 [revised]
PHST- 2022/06/17 00:00 [accepted]
PHST- 2022/06/24 01:42 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/25 06:01 [medline]
PHST- 2022/06/19 00:00 [pmc-release]
AID - vaccines10060974 [pii]
AID - vaccines-10-00974 [pii]
AID - 10.3390/vaccines10060974 [doi]
PST - epublish
SO  - Vaccines (Basel). 2022 Jun 19;10(6):974. doi: 10.3390/vaccines10060974.